SFM
FRTX

Soros Fund Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Soros Fund Management’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-18
Closed -$71K – 365
2014
Q2 		$71K Buy
+18
New +$67.7K ﹤0.01% 336

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return

Soros Fund Management's FRTX Position: Q3 2014 in Review

Soros Fund Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2014, closing a stake of 18 shares — an estimated $71K sold.

Soros Fund Management first reported a position in FRTX in Q2 2014 and held it in 1 quarter. The position peaked at $71K in Q2 2014. 60 funds tracked by Wall St. Rank hold FRTX as of Q3 2014.

  • Soros Fund Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • Soros Fund Management sold 18 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $71K.
  • Soros Fund Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2014 and held it in 1 quarter.
  • Soros Fund Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $71K in Q2 2014.
  • 60 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2014.

Based on Soros Fund Management's 13F filing for Q3 2014, filed 14 Nov 2014.